Notably, a small peptide derived from a conserved stretch of NUDT13 was sufficient to inhibit CRC initiation and growth, signifying NUDT13 as a promising target for therapeutic exploitation in CRC. The gene discussed is NUDT13; the disease is colorectal carcinoma.